According to a study published in The BMJ, while e-cigarettes can assist smokers to quit, the number of days of e-cigarette use will determine quit attempt and quit success.
While e-cigarettes can assist smokers to quit, the number of days of e-cigarette use will determine quit attempt and quit success, according to a study published in The BMJ.
Researchers at the University of California, San Francisco, who conducted the study analyzed data from the US Current Population Survey-Tobacco Use Supplement (2001-2002, 2003, 2006-2007, 2010-2011, and 2014-2015), but e-cigarette use was obtained only from the total sample (n = 161,054) from the 2014-2015 survey. Smoking cessation rates were obtained from those who quit smoking cigarettes 12 months prior to the survey (n = 23,270) and compared with the quit rates from the 2010-2011 survey and 3 others.
The primary outcome measures were the rate of attempt to quit cigarette smoking and the rate of successful quitting (meaning having abstained from cigarette smoking for 3 months).
Of the 2014-2015 sample, 22,548 were current smokers and 2136 were recent quitters—38.2% of current smokers and 49.3% of recent quitters had tried e-cigarettes. Of this subpopulation, 11.5% and 19%, respectively, currently use e-cigarettes and were the more likely population to quit smoking: 65.1% vs 40.1%. they also stood a much greater chance of quit success (8.2% vs 4.8%).
The authors write that while only 1.4% of smokers were current users of e-cigarettes in 2010, the number rose to between 15% and 30% by 2014; this meant that comparing the quit rates for those 2 periods would provide the most accurate impact of e-cigarette use on quitting.
E-cigarettes appear to have helped to increase smoking cessation at the population level, the authors conclude based on their study results.
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More